Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio
Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.
Mental health crisis could cost the world $16 trillion by 2030
Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.
Impatient patients turn to online ‘buyers club’ for new drugs
Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.
CDC: 14 Million Americans Will Have Alzheimer’s by 2060
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Lilly migraine drug wins European panel thumbs-up
A European Medicines Agency panel recommended the approval of U.S. pharmaceutical group Eli Lilly’s migraine treatment, bringing the drug one step closer to being sold in the European Union.
Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference
Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).
Pharmaceutical companies: 3 mindset shifts to deal with a drying pipeline
The difficulty behind new ideas, project management, drug prices, and the slowness and uncertainty of new product development are just some external and internal roadblocks that pharmaceutical leaders and employees face.
Novartis Halts Planned Price Increases For Drugs Amid Scrutiny of Relationship With Trump Attorney
Novartis is halting planned price increases on the Swiss pharma giant’s medications after President Donald Trump took Pfizer to task over price hikes, with Pfizer subsequently agreeing to roll back the company’s price increases.
Prothena Slashes 57% of Employees in Reorganization
One month after Prothena Corporation shuttered its NEOD001 program for AL amyloidosis following a Phase IIb failure, the company initiated a reorganization.
Amgen’s Aimovig halved migraine days in 30 percent of trial patients
A late-stage trial of Amgen Inc.’s Aimovig found that the experimental drug reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
October 2018 Focus: Top 50 Pharma, Company of the Year and more!